{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-23-000033","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.013448+00:00","generated_at":"2026-06-15T09:24:36.119063+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Shattuck Labs reports Q1 net loss $20.7M; cash $135.5M; clinical milestones on track","bullets":["Net loss $20.7M ($0.49 per share) vs $24.5M ($0.58 per share) in Q1 2022.","Cash and investments $135.5M at March 31, 2023, expected to fund operations through year-end 2024.","R&D expenses $16.7M (down from $19.2M); G&A $5.1M (flat YoY).","Complete Phase 1A monotherapy data for SL-172154 in PROC to be presented at ASCO June 2023.","Initial Phase 1B combo data (liposomal doxorubicin) expected mid-2023; mirvetuximab combo trial dosed first patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-23-000033","json":"https://secwatch.observer/filing/0001680367-23-000033.json","markdown":"https://secwatch.observer/filing/0001680367-23-000033.md","text":"https://secwatch.observer/filing/0001680367-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036723000033/0001680367-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036723000033/sttk-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:24:36.119063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"827b93815baf7b964ab14251699f8e357ac52dc4","claim":"Shattuck Labs, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 9, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680367/000168036723000033/0001680367-23-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}